Chemkart India has invested ₹10 lakh in its wholly-owned subsidiary, Vinstar Biotech Private Limited, through a rights issue. The investment was made to support the subsidiary's capital expenditure and working capital requirements.

The company allotted 1,00,000 equity shares with a face value of ₹10 each at an issue price of ₹10 per share. Following this allotment, Chemkart India continues to hold 100% of the shareholding in Vinstar Biotech. The transaction was conducted at arm's length and falls under the ambit of related party transactions.

Vinstar Biotech is an R&D-driven nutraceutical company incorporated in 2023. It specializes in proprietary bioactive technologies and the commercial distribution of health and nutraceutical products. The entity focuses on liposomal and microencapsulated delivery platforms to enhance the bioavailability of health supplements, vitamins, and amino acids.

As of March 31, 2026, Vinstar Biotech reported a turnover of ₹223.43 Lakhs. The entity recorded a loss after tax of ₹24.72 Lakhs and a net worth of negative ₹34.69 Lakhs. The subsidiary had no turnover in the financial years 2023-24 and 2024-25.

Financial Details of Vinstar Biotech

Jaini Shailesh Mehta, a member of the promoter group at Chemkart India Limited , has increased her shareholding by acquiring 2,400 equity shares through open market transactions on BSE Limited. The transactions were executed on June 12 and June 18, 2026, as disclosed under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. This acquisition raises the acquirer's stake in the company, though the overall equity capital remains unchanged.

The filing details that the face value of each equity share is INR 10. Prior to these transactions, Mehta held 1,807 shares, representing 0.01% of the company's equity share capital. Following the acquisition of 2,400 shares, her total holding stands at 4,207 shares, which constitutes 0.03% of the total paid-up equity share capital.

The total equity share capital of Chemkart India Limited remains INR 12,09,90,000, comprising 1,20,99,000 equity shares of INR 10 each. The disclosure confirms that the mode of acquisition was strictly through the open market on BSE Limited, with no other modes of disposal or acquisition reported in this specific filing.

Breakdown of Shareholding

The following table outlines the changes in shareholding for Jaini Shailesh Mehta following the recent acquisitions:

The disclosure was submitted to BSE Limited and acknowledged by the company's compliance officer. The regulatory filing ensures transparency regarding the substantial acquisition of shares by the promoter group member.